Legacy Advisors LLC lifted its position in shares of Pfizer Inc. (NYSE:PFE) by 8.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 9,032 shares of the biopharmaceutical company’s stock after purchasing an additional 725 shares during the period. Legacy Advisors LLC’s holdings in Pfizer were worth $327,000 at the end of the most recent reporting period.
Other institutional investors have also recently added to or reduced their stakes in the company. Kinloch Capital LLC purchased a new stake in shares of Pfizer during the 4th quarter worth $25,000. Alpha DNA Investment Management LLC purchased a new stake in Pfizer in the fourth quarter valued at $26,000. Penbrook Management LLC purchased a new stake in Pfizer in the fourth quarter valued at $27,000. Orion Capital Management LLC purchased a new stake in Pfizer in the fourth quarter valued at $29,000. Finally, Merrion Investment Management Co LLC purchased a new stake in Pfizer in the fourth quarter valued at $30,000. 67.36% of the stock is owned by institutional investors and hedge funds.
PFE traded up $0.15 on Monday, hitting $36.75. 412,606 shares of the company were exchanged, compared to its average volume of 31,853,941. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.13 and a current ratio of 1.40. The firm has a market capitalization of $204.98 billion, a P/E ratio of 23.52, a price-to-earnings-growth ratio of 2.79 and a beta of 0.70. The business’s fifty day moving average is $35.11 and its 200 day moving average is $36.57. Pfizer Inc. has a fifty-two week low of $31.61 and a fifty-two week high of $43.08.
Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 2nd. The biopharmaceutical company reported $0.42 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.46 by ($0.04). The firm had revenue of $11.68 billion for the quarter, compared to analysts’ expectations of $11.32 billion. Pfizer had a net margin of 17.85% and a return on equity of 24.88%. The business’s quarterly revenue was up 11.8% on a year-over-year basis. During the same period in the previous year, the company posted $0.55 EPS. Analysts forecast that Pfizer Inc. will post 2.89 EPS for the current fiscal year.
A number of brokerages recently weighed in on PFE. Morgan Stanley reduced their price target on shares of Pfizer from $40.00 to $38.00 and set an “equal weight” rating for the company in a research report on Friday, January 29th. TheStreet cut shares of Pfizer from a “b” rating to a “c+” rating in a report on Friday, March 5th. Berenberg Bank reaffirmed a “neutral” rating and issued a $38.00 target price on shares of Pfizer in a report on Tuesday, March 23rd. DZ Bank reaffirmed a “buy” rating and issued a $41.00 target price on shares of Pfizer in a report on Wednesday, February 3rd. Finally, Royal Bank of Canada assumed coverage on shares of Pfizer in a report on Wednesday, April 7th. They issued a “sector perform” rating and a $42.00 target price for the company. Eleven research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Pfizer presently has a consensus rating of “Hold” and a consensus price target of $38.47.
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands.
Recommended Story: Inflation
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).